Colorectal cancer NCCN guidelines 2026

Colorectal cancer (CRC), in fact, still represents one of the greatest oncologic challenges we are facing today. It represents the fourth most common cancer diagnosis and the second most common cause of cancer-related mortality in the United States.

PubMed: In light of these facts, it is clear that the National Comprehensive Cancer Network (NCCN) continues to fine-tune its treatment recommendations and in fact, the 2026 updates represent a significant evolution in the way we treat both colon and rectal cancer.

One of the defining themes of the 2026 guidelines is the increasing importance of molecular profiling as a factor in therapy selection. The selection of therapy is based on several considerations, including the goals of therapy, type and schedule of therapy, tumor mutational profile, and differing toxicities of the drugs used.

PubMed clinicians must now evaluate mismatch repair status, BRAF mutation status, RAS mutations, HER2 amplification, and NTRK fusion status before selecting a therapy path. The most recent addition to this list is DPYD genetic variant testing, as the NCCN guidelines now recommend that such testing be considered prior to the start of fluoropyrimidine therapy, according to ASCO Post, as these variants can have a profound effect on the risk of severe toxicity from these drugs, which are very commonly used.

One of the most important changes is for patients with BRAF V600E-mutated metastatic colorectal cancer, a group that has traditionally had a poor prognosis. Based on data from the phase III BREAKWATER trial, first-line treatment of BRAF V600E-mutated metastatic colorectal cancer with FOLFOX in combination with encorafenib and cetuximab or panitumumab is now recommended, as it has shown superior outcomes in a group of patients that traditionally has a poor prognosis.

Onclive, specifically encorafenib in combination with cetuximab and FOLFOX, is now recommended as initial intensive therapy (category 2A) and as second-line and subsequent biomarker-directed therapy (category 2B).

In patients whose tumors show mismatch repair deficiency (dMMR) or microsatellite instability high (MSI-H), checkpoint inhibitors are not held back for later-line therapy.

This change reflects the addition of checkpoint inhibitor therapies at earlier points of the patient journey. Onclive: There are multiple therapies in this space, and they include pembrolizumab, nivolumab alone or in combination with ipilimumab, dostarlimab, cemiplimab, and others, providing a variety of options for oncologists and patients based on their specific circumstances.

Significant changes have been noted in the rectal cancer guideline. FOLFIRINOX chemotherapy has been added as an option for neoadjuvant chemotherapy for patients with MSS/pMMR rectal cancer and resectable synchronous liver-only and/or lung-only metastases.

ASCO Post In the meantime, the "watch and wait" strategy for patients with a complete clinical response to immunotherapy or chemoradiation is being increasingly validated. Immune checkpoint inhibitor therapy is now recommended instead of total neoadjuvant therapy (TNT) for locally advanced dMMR/MSI-H rectal cancers.

The updated 2026 NCCN guidelines for colorectal cancer treatment are a clear progression towards more personalized treatment, more molecularly focused treatment, and more immunologically focused treatment starting earlier on. For anyone facing a diagnosis of colorectal cancer, it’s clear that biomarker testing should be done at diagnosis and that treatment should be done in a facility that’s familiar with current treatment algorithms.

Note: Always consult your oncologist or a specialist to understand how these guidelines apply to your specific situation. Treatment decisions should be made in the context of individual clinical circumstances.